Last Price$488.3(2.3%)
Market Cap$124.8B
LTM Income Tax
$784.1M
YoY Growth
+3.1%
3Y CAGR
+26.4%
5Y CAGR
+29.2%
Stock quality & Intrinsic value
6/10
61.6% overvalued
Vertex Pharmaceuticals Incorporated Income Tax
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Tax | $61.7M | ($18.5M) | ($21.4M) | ($30.7M) | $19.3M | $19.3M | $19.3M | $38.8M | ($288.6M) | $6,958.0K | $30.4M | $16.7M | ($107.3M) | ($1,486.9M) | $218.1M | $405.2M | $388.3M | $910.4M | $760.2M | $784.1M |
Overvalued or undervalued?
Check the intrinsic value for VRTX
and see if it's the right time to invest.
Vertex Pharmaceuticals Incorporated (VRTX) Income Tax comparison analysis
General
LTM Income Tax
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Vertex Pharmaceuticals IncorporatedVRTX
$784.1M
3.1%
26.4%
29.2%
Median Peer Set
$140.7M
8.9%
0.0%
0.0%
Regeneron Pharmaceuticals, Inc.REGN
$367.3M
49.5%
(33.5%)
3.2%
United Therapeutics CorporationUTHR
$343.9M
18.8%
42.8%
N/A
Incyte CorporationINCY
$284.0M
20.0%
N/A
48.1%
Royalty Pharma plcRPRX
$209.3M
(63.0%)
(30.5%)
(9.7%)
BeiGene, Ltd.BGNE
$166.6M
17.8%
N/A
N/A
BioMarin Pharmaceutical Inc.BMRN
$114.9M
449.3%
N/A
N/A
Summit Therapeutics Inc.SMMT
$2,962.0K
(99.7%)
7.0%
N/A
BioNTech SEBNTX
($13.4M)
N/A
N/A
115.1%
argenx SEARGX
($22.2M)
(55.7%)
N/A
N/A
Alnylam Pharmaceuticals, Inc.ALNY
($99.2M)
N/A
N/A
N/A
VRTX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 160.9 56.6% | 216.4 34.5% | 199.0 (8.0%) | 175.5 (11.8%) | 102.0 (41.9%) | 143.4 40.5% | 1,410.6 883.9% | 1,527.0 8.3% | 1,212.0 (20.6%) | 580.4 (52.1%) | 1,032.3 77.9% | 1,702.2 64.9% | 2,488.7 46.2% | 3,047.6 22.5% | 4,162.8 36.6% | 6,205.7 49.1% | 7,574.4 22.1% | 8,930.7 17.9% | 9,869.2 10.5% | 11,020.1 11.7% |
| Cost of Goods Sold (COGS) | 10.1 | 12.2 | 13.9 | 15.7 | 14.2 | 12.7 | 80.5 | 279.9 | 130.3 | 61.0 | 125.5 | 210.5 | 275.1 | 409.5 | 547.8 | 736.3 | 904.2 | 1,080.3 | 1,262.2 | 1,530.5 |
% margin | 150.8 93.7% | 204.2 94.4% | 185.1 93.0% | 159.8 91.1% | 87.8 86.1% | 130.6 91.1% | 1,330.1 94.3% | 1,247.2 81.7% | 1,081.7 89.3% | 519.4 89.5% | 906.8 87.8% | 1,491.7 87.6% | 2,213.5 88.9% | 2,638.1 86.6% | 3,615.1 86.8% | 5,469.4 88.1% | 6,670.2 88.1% | 7,850.4 87.9% | 8,607.0 87.2% | 9,489.6 86.1% |
| Operating Expenses | 292.5 | 429.6 | 597.8 | 618.2 | 680.0 | 825.2 | 1,108.4 | 1,243.0 | 1,281.1 | 1,160.9 | 1,373.3 | 1,480.5 | 1,820.7 | 1,974.1 | 2,413.0 | 2,600.0 | 3,891.2 | 3,485.0 | 4,775.0 | 9,722.5 |
| Research & Development Expenses (R&D) | 248.5 | 371.7 | 513.1 | 516.3 | 550.7 | 637.4 | 707.7 | 806.2 | 918.8 | 855.5 | 996.2 | 1,047.7 | 1,324.6 | 1,416.5 | 1,754.5 | 1,829.5 | 3,051.1 | 2,540.3 | 3,162.9 | 3,630.3 |
| Selling, General & Administrative Expenses (SG&A) | 44.0 | 57.9 | 84.7 | 101.9 | 129.3 | 187.8 | 400.7 | 436.8 | 362.3 | 305.4 | 377.1 | 432.8 | 496.1 | 557.6 | 658.5 | 770.5 | 840.1 | 944.7 | 1,136.6 | 1,464.3 |
% margin | (149.9) (93.2%) | (229.0) (105.9%) | (419.8) (210.9%) | (462.7) (263.6%) | (613.4) (601.1%) | (696.1) (485.5%) | 113.8 8.1% | 2.3 0.2% | (903.4) (74.5%) | (692.4) (119.3%) | (468.7) (45.4%) | 9.9 0.6% | 123.2 5.0% | 635.2 20.8% | 1,197.6 28.8% | 2,856.3 46.0% | 2,782.1 36.7% | 4,307.4 48.2% | 4,307.5 43.6% | (232.9) (2.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 16.3 | 5.0 | 2.0 | 1.9 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 11.7 | 0.0 | 63.7 | 22.2 | 4.9 | 144.6 | 614.7 | 598.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 13.5 | 13.2 | 19.3 | 36.6 | 14.7 | 22.7 | 72.9 | 84.2 | 81.4 | 57.6 | 34.1 | 58.5 | 58.2 | 61.5 | 54.8 | 44.1 | 30.6 |
| Pre-tax Income | (173.4) | (206.9) | (426.9) | (464.2) | (642.2) | (754.6) | 60.4 | (12.4) | (976.1) | (734.9) | (559.6) | (67.4) | (15.7) | 600.2 | 1,394.9 | 3,116.8 | 2,730.4 | 4,232.4 | 4,379.8 | 248.5 |
% effective tax rate | 61.7 (35.6%) | (18.5) 8.9% | (21.4) 5.0% | (30.7) 6.6% | 19.3 (3.0%) | 19.3 (2.6%) | 19.3 31.9% | 38.8 (313.0%) | (288.6) 29.6% | 7.0 (0.9%) | 30.4 (5.4%) | 16.7 (24.7%) | (107.3) 684.1% | (1,486.9) (247.7%) | 218.1 15.6% | 405.2 13.0% | 388.3 14.2% | 910.4 21.5% | 760.2 17.4% | 784.1 315.5% |
% margin | (203.4) (126.4%) | (206.9) (95.6%) | (391.3) (196.6%) | (459.9) (262.0%) | (641.6) (628.7%) | (754.6) (526.3%) | 29.6 2.1% | (107.0) (7.0%) | (445.0) (36.7%) | (738.6) (127.2%) | (558.1) (54.1%) | (112.1) (6.6%) | 263.5 10.6% | 2,096.9 68.8% | 1,176.8 28.3% | 2,711.7 43.7% | 2,342.1 30.9% | 3,322.0 37.2% | 3,619.6 36.7% | (535.6) (4.9%) |
| EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.32) | (0.46) | 1.06 | 8.25 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | (2.08) |
| Diluted EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.31) | (0.46) | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | (2.08) |
% margin | (114.4) (71.1%) | (199.5) (92.2%) | (385.2) (193.6%) | (426.2) (242.8%) | (598.9) (586.9%) | (704.9) (491.7%) | 133.9 9.5% | 42.5 2.8% | (554.8) (45.8%) | (598.8) (103.2%) | (411.3) (39.8%) | 75.5 4.4% | 103.3 4.1% | 706.8 23.2% | 1,560.4 37.5% | 3,284.5 52.9% | 2,917.5 38.5% | 4,435.5 49.7% | 4,605.2 46.7% | 486.3 4.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Vertex Pharmaceuticals Incorporated's Income Tax?
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Income Tax is $784.1M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Vertex Pharmaceuticals Incorporated's Income Tax growth rate?
Over the last year, Vertex Pharmaceuticals Incorporated's Income Tax growth was 3.1%. The average annual Income Tax growth rates for Vertex Pharmaceuticals Incorporated have been 23.2% over the past three years, 29.2% over the past five years.